

Dr. Jorge Gallardo Ballart

Professional profile and biography

Dr. Jorge Gallardo has a PhD in Industrial Engineering from the Escuela Técnica Superior de Ingeniería Industrial in Barcelona, and has been Chairman of Almirall since 1988, having previously held various management positions in the company (including that of Chief Executive Officer until 2011) since his incorporation in 1965. He was Chairman of the EFPIA (European Federation of Pharmaceutical Industries and Associations) from 1998 to 2018. He was also Chairman of Farmaindustria from 1993 to 1995, and more recently from 2002 to 2004, and is currently Vice Chairman. Dr. Gallardo also belongs to the Boards of Directors of Grupo Plafin, S.A. and Grupo Corporativo Landon, S.L.

Other significant Boards to which he belongs, listed companies or otherwise

Grupo Plafin, S.A., Walton, S.L., Goodgrower, S.A.

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External proprietary member, linked to Grupo Plafin, S.A. and Grupo Corporativo Landon, S.L.

Date of first appointment as company board member, and subsequent appointments

First appointment on 30/06/1997. Re-elected on 18/10/2006, 04/05/2012, 09/05/2018 and 08/05/2019.

Company shares, and share options, of which he is holder

He is indirect holder, with his brother Antonio through the company Grupo Plafin, S.A., of 71.429.287 company shares, and indirect holder, with his brother Antonio through the company Grupo Corporativo Landon, S.L., of 32.830.765 company shares.

Mr. Gianfranco Nazi

Professional profile and biography

Gianfranco Nazi holds a Degree in Economics and Banking Sciences from the University of Udine and a Master's Degree of Business Administration from the Bocconi University of Milan. Mr. Nazi joins Almirall from Teva Pharmaceuticals Industries Ltd, where he has most recently been serving as Executive Vice President of the International Markets Region and as a member of the Teva Executive Committee. While at Teva over the past seven years, he held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. Mr. Nazi held the position of Senior Vice President Specialty Medicines Europe and President and CEO Growth Markets Region. Prior to Teva, Mr. Nazi held a variety of senior positions at Astra Zeneca, GSK and Eli Lilly in commercial and general management roles based in the UK, Italy, Serbia and the US.

Other significant Boards to which he belongs, listed companies or otherwise

None

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

Executive director

Date of first appointment as company board member, and subsequent appointments

18/02/21, by co-option; reelected by the General Assembly on 07/05/21

Company shares, and share options, of which he is holder

None

Sir Tom McKillop

Professional profile and biography

Sir Tom McKillop began his career at ICI where he held various positions before being appointed Technical Director. In 1992 he was appointed deputy CEO and in 1994 he became CEO of Zeneca Pharmaceuticals, leading the merger of Astra and Zeneca in 1999, and becoming CEO of AstraZeneca plc until retiring at the end of 2005. Until 2009, he was the Chairman of the Royal Bank of Scotland and a Non-Executive Director of BP. He has been Chairman or non-executive director of various other healthcare companies and received numerous academic awards and honorary degrees.

Other significant Boards to which he belongs, listed companies or otherwise

Evolva Holding SA. He is also part of the Advisory Board of Alsbridge LLP.

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External member.

Date of first appointment as company board member, and subsequent appointments

First appointment on 29/05/2007. Re-elected on 04/05/2012, 09/05/2018 and 08/05/2019.

Company shares, and share options, of which he is holder

No shares or share options.

Mr. Gerhard Mayr

Professional profile and biography

Mr. Mayr holds a Degree in Chemical Engineering from the Swiss Federal Institute of Technology, and an MBA from the Stanford Graduate School of Business. He joined Eli Lilly & Company in 1972 as a sales representative and retired in 2004 as Executive Vice President of Global Pharmaceutical Operations, having held management positions in the U.S., Europe, Middle East, Asia and Latin America. In addition, he was Chairman and Board Member in several companies. He continues to serve as Board Member in several companies and organizations.

Other significant Boards to which he belongs, listed companies or otherwise

Lonza Group Ltd., GVKBio.

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked.

Independent.

Date of first appointment as company board member, and subsequent appointments.

First appointment on 19/10/2012. Re-elected on 08/05/2019.

Company shares, and share options, of which he is holder

None.

Ms. Karin Louise Dorrepaal

Professional profile and biography

Mrs. Dorrepaal has a PhD from the Free University of Amsterdam, and holds an MBA from the Rotterdam School of Management. In 1990 she joined Booz Allen Hamilton, Management Consultants, where she remained until 2004, being appointed Vice President (partner) in 2000. She specializes in the pharmaceutical industry and has advised large companies on strategy, sales, marketing and supply chain issues. In 2004 she was appointed to the Board of Executive Directors of Schering AG. Following the acquisition of this company by Bayer AG, Ms. Dorrepaal left her position. Currently she is on the Board of Directors of Gerresheimer AG, Paion AG, the Kerry Group plc. and several non-listed companies.

Other significant Boards to which she belongs, listed companies or otherwise

Gerresheimer AG, Paion AG, The Kerry Group plc.

Member category to which she belongs as applicable, indicating, for directors representing controlling shareholders, the shareholder she represents or with whom she is linked

Independent.

Date of first appointment as company board member, and subsequent appointments

First appointment on 16/11/2012 by co-option, effective as of 01/01/2013. Re-elected on 08/05/2019.

Company shares, and share options, of which she is holder

None.

Dr. Seth J. Orlow, M.D., Ph.D.

Professional profile and biography

Dr. Orlow holds a Bachelor of Medicine and PhD in Molecular Pharmacology from the Albert Einstein College of Medicine of Yeshiva University (USA) and a Bachelor of Science in Biomedical Sciences from Harvard College (USA). He has been Senior consultant to Pharus Advisors, Chairman and Professor of Dermatology at New York University School of Medicine and Member of the Advisory Board of Dermira Inc. and Provectus Pharmaceuticals, Inc. In the past, Dr. Orlow was, among others, a partner at Easton Capital Partners, co-founder of Anaderm Research Corporation, and a director of Protez Pharmaceuticals and Transave. He also belongs to the Board of Directors of R2 Technologies, Inc.

Other significant Boards to which he belongs, listed companies or otherwise

R2 Technologies, Inc. (privately held)

Member category to which he belongs as applicable, indicating, for directors representing controlling shareholders, the shareholder she represents or with whom she is linked

Independent.

Date of first appointment as company board member, and subsequent appointments

First appointment on 06/05/2016. Re-elected on 23/07/2020

Shares or options on shares in the Company

None.

Ms. Georgia Garinois-Melenikiotou

Professional profile and biography

Mrs. Garinois-Melenikiotou holds a Degree in Mechanical Engineering from the National Technical University of Athens, and Master's in Management from the Massachusetts Institute of Technology. She is the Executive Vice President of Corporate Marketing at the Estée Lauder Companies, Inc., and Board Member of the MIT Sloan School of Management and Operating Partner at Talomon Capital LTD. Before joining Estée Lauder in 2010, Ms Garinois-Melenikiotou held various management positions up to Global President at Johnson & Johnson, where she remained for 27 years and worked in seven countries.

Other significant Boards to which she belongs, listed companies or otherwise

None.

Member category to which she belongs as applicable, indicating, for directors representing controlling shareholders, the shareholder she represents or with whom she is linked

Independent.

Date of first appointment as company board member, and subsequent appointments First appointment

First appointment on 06/05/2016 by cooption, effective as of 01/07/2016. Ratified and re- elected on 03/05/2017

Shares or options on shares in the Company

None.

Mr. Enrique D Leyva Pérez

Professional profile and biography

Mr. De Leyva holds a Degree in Civil Engineering from the Engineering School of Madrid and an MBA from Columbia Business School, where he was a Fulbright Scholar and specialised in Finance and Accounting. He has developed his career in top-level companies such as Unión Fenosa and McKinsey & Company in various executive positions and countries (including the UK and USA), and is currently one of the founding partners of Magnum Industrial Partners, a leading Iberian private equity firm. He also belongs to the Boards of Directors of Indra as well as several portfolio companies of the Magnum funds.

Other significant Boards to which he belongs, listed companies or otherwise

Indra, Nace, Iberchem, Vendap y Orliman.

Member category to which she belongs as applicable, indicating, for directors representing controlling shareholders, the shareholder she represents or with whom she is linked

Independent.

Date of first appointment as company board member, and subsequent appointments

First appointment on 22/02/2019 by co-option. Ratified and re-elected on 08/05/2019.

Shares or options on shares in the Company

17.980 shares.

Mr. Carlos Gallardo Piqué

Professional profile and biography

Mr. Carlos Gallardo holds a Degree in Industrial Engineering from the Polytechnic University of Catalonia and MBA from Stanford University (US). With extensive experience in the pharmaceutical sector, he has held management positions at Pfizer and Almirall, mainly in the areas of Licensing, Business Development and Country Management. He was General Manager of Almirall's subsidiary in the UK and Ireland. Previously, he worked in the automotive sector as an expert and manager of industrial organisation. In 2014 Mr. Carlos Gallardo founded CG Health Ventures where he serves as the Managing Director. CG Health Ventures builds digital health companies and invests in early stage health technology companies globally.

Other significant Boards to which he belongs, listed companies or otherwise

None.

Member category to which he belongs, as applicable, indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External member linked to Grupo Plafin, S.A.U. and Grupo Corporativo Landon, S.L.

Date of first appointment as company board member, and subsequent appointments

First appointment 25/07/2014 by co-option. Ratified and re-elected on 07/11/2014 and re- elected again on 08/05/2019.

Company shares, and share options, of which he is holder

Direct holder of 1.000 shares and indirect holder, together with other family members through Grupo Plafin, S.A.U., of 71.429.287 company shares and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 32.830.765 company shares.

Mr. Antonio Gallardo Torrededía

Professional profile and biography

Mr. Antonio Gallardo holds a degree in Business Science from the University of Barcelona and an Executive MBA from the University of Chicago. He also has a Master's degree in Marketing from ESADE. He developed his first professional stage in Akzo Nobel during 7 years, reaching the position of Marketing Director, and in 1999 he joined Almirall as area manager. Later he was Director of Pharmacy Marketing, after which he joined the medical visit network as Area Manager and later as Division Chief. In 2008 he left Almirall to continue in the family business, where he took charge of the real estate area.

Other significant Boards to which he belongs, listed companies or otherwise

None

Member category to which he belongs, as applicable, indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External member linked to Grupo Plafin, S.A.U. and Grupo Corporativo Landon, S.L.

Date of first appointment as company board member, and subsequent appointments

First appointment 25/07/2014 by co-option. Ratified and re-elected on 07/11/2014 and re-elected again on 08/05/2019.

Company shares, and share options, of which he is holder

Direct holder of 182 shares and indirect holder, together with other family members through Grupo Plafin, S.A.U., of 71.429.287 company shares and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 32.830.765 company shares.

Ms. Alexandra B. Kimball

Professional profile and biography

Ms. Alexandra B. Kimball holds an AB in Molecular Biology (Princeton University), a MD (Yale University School of Medicine) and a MPH (Johns Hopkins School of Public Health). Ms. Kimball is, among others, the President and CEO, Harvard Medical Faculty Physicians (HMFP) at Beth Israel Deaconess Medical Center, member of its Board of Directors and a dermatologist in such Center, and is a Professor of Dematology at Harvard Medical School, as well as the Co-Chair of the Management Board at Beth Israel Lahey Health Performance Network (BILPN) and President of Physicians LLC at Beth Israel Deaconess Care Organization (BIDCO). In addition, Ms. Kimball has held several relevant positions in prestigious medical and academic institutions and companies.

Boards of Directors of relevance to which Ms.Kimball belongs, whether in listed or non-listed companies

Beth Israeli Lahey Health, Beth Israel Deaconess Medical Center, Physicians LLC.

Director category

Independent.

Shares or options on shares in the Company

None.

Ms. Eva-Lotta Coulter (Known as Allan)

Professional profile and biography

Ms. Eva-Lotta Coulter holds a degree in Natural Sciences from Jakobsbergskolan (Stockholm) and Microbiology from the Laboratory School University (Stockholm), and a Master Certificate in Marketing from the Institute for Higher Marketing Business School (Stockholm). Ms. Coulter is Chairman and member of the Audit and Remuneration Committee at Draupnir Bio, Chairman and member of the Nomination Committee at C4X Discovery, Non-Executive Director of Aleta Biotherapeutics and Crescendo Biologics, and Non-Executive Director and member of the Corporate Governance Committee and the R&D Subcommittee at Targovax ASA.

Boards of Directors of relevance to which Ms. Coulter belongs, whether in listed or non-listed companies

Aleta Biotherapeutics, Crescendo Biologics, C4X Discovery, Draupnir Bio and Targovax ASA.

Director category

Independent.

Shares or options on shares in the Company

None.

Mr. Ruud Dobber

Professional profile and biography

Master of Science (University of Utrecht, The Netherlands) and PhD in Immunology (University of Leiden, The Netherlands). Mr. Dobber was appointed in January 2019 Executive Vice-President, BioPharmaceuticals Business in AstraZeneca and is responsible for product strategy and commercial delivery for Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology. Prior to this, Mr. Dobber held several executive roles at AstraZeneca, among others President at AstraZeneca US and Executive Vice-President North America, Executive Vice-President Europe, Regional Vice-President Europe, Middle East and Africa, Regional Vice-President Asia Pacific or Area Vice-President Europe 1. In addition, Mr. Dobber was a member of the Board and Executive Committee of EFPIA and Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America.

Other significant Boards to which he belongs, listed companies or otherwise

None

Member category

Independent director

Date of first appointment as company board member, and subsequent appointments

18/06/21, by the Shareholders Meeting

Company shares, and share options, of which he is holder.

None